E76.219 Morquio mucopolysaccharidoses, unspecified

Name of the Condition

• Morquio mucopolysaccharidoses, unspecified (ICD-10 Code: E76.219)

Summary

Morquio mucopolysaccharidoses, unspecified, are rare inherited disorders characterized by the accumulation of glycosaminoglycans (GAGs) due to enzyme deficiencies. This buildup disrupts normal cellular function, leading to progressive multisystem involvement, including skeletal abnormalities, organ enlargement, and neurological impairment. Early recognition and management are important to address complications and slow disease progression.

Causes

The disorder is caused by genetic mutations that impair enzymes responsible for breaking down glycosaminoglycans. These mutations result in the accumulation of undegraded GAGs in cells, tissues, and organs, disrupting normal structure and function. The specific enzyme deficiency determines the type and severity of the condition.

Risk Factors

• Family history of mucopolysaccharidoses or related lysosomal storage disorders.
• Consanguineous relationships (increased risk of recessive inheritance).
• Ethnic or geographic populations with higher carrier rates for specific mutations.

Symptoms

• Skeletal abnormalities, such as short stature, joint stiffness, or dysostosis multiplex.
• Organ enlargement (e.g., hepatosplenomegaly).
• Neurological symptoms, including developmental delay, seizures, or cognitive impairment.
• Coarse facial features.

Diagnosis

Diagnosis involves clinical evaluation, biochemical testing for GAG levels, and genetic testing to identify specific mutations. Imaging studies may assess skeletal abnormalities, while enzyme activity assays confirm the underlying deficiency.

Treatment Options

Treatment focuses on managing symptoms and complications, including physical therapy, surgical interventions for skeletal issues, and enzyme replacement therapy (if available). Supportive care addresses organ dysfunction and neurological symptoms.

Prognosis and Follow-Up

Prognosis varies based on severity and organ involvement. Regular follow-up with multidisciplinary care (e.g., orthopedics, neurology, pulmonology) is essential to monitor disease progression and adjust management strategies.

Complications

• Respiratory insufficiency due to skeletal abnormalities.
• Cardiac valve disease.
• Vision or hearing loss.
• Progressive neurological decline.

Lifestyle & Prevention

• Genetic counseling for families with a history of the disorder.
• Early intervention programs to support developmental needs.
• Regular monitoring of organ function to address complications promptly.

When to Seek Professional Help

Seek medical attention for new or worsening symptoms, such as severe joint pain, breathing difficulties, or neurological changes, to prevent irreversible damage.

Tips for Medical Coders

Use E76.219 for cases where Morquio mucopolysaccharidoses are diagnosed but the specific subtype (e.g., Morquio A or B) is not documented. Ensure documentation supports the unspecified classification and aligns with clinical findings.